Imunon (NASDAQ:IMNN) Given “Buy” Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Imunon (NASDAQ:IMNN) in a report issued on Friday,Benzinga reports. They currently have a $29.00 price target on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Imunon in a report on Thursday, December 19th.

Imunon Price Performance

IMNN stock opened at $0.96 on Friday. The firm has a 50-day moving average price of $0.86 and a 200-day moving average price of $1.03. Imunon has a 12 month low of $0.48 and a 12 month high of $3.65.

Imunon (NASDAQ:IMNN) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.03. During the same period last year, the business earned ($0.37) earnings per share. On average, analysts anticipate that Imunon will post -1.68 earnings per share for the current fiscal year.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.